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ABSTRACT The development of a functional biomarker assay in the tuberculosis
(TB) ﬁeld would be widely recognized as a major advance in efforts to develop and
to test novel TB vaccine candidates efﬁciently. We present preliminary studies using
mycobacterial growth inhibition assays (MGIAs) to detect Mycobacterium bovis BCG
vaccine responses across species, and we extend this work to determine whether a
standardized MGIA can be applied in characterizing new TB vaccines. The compara-
tive MGIA studies reviewed here aimed to evaluate robustness, reproducibility, and
ability to reﬂect in vivo responses. In doing so, they have laid the foundation for the
development of a MGIA that can be standardized and potentially qualiﬁed. A major
challenge ahead lies in better understanding the relationships between in vivo pro-
tection, in vitro growth inhibition, and the immune mechanisms involved. The ﬁnal
outcome would be a MGIA that could be used with conﬁdence in TB vaccine trials.
We summarize data arising from this project, present a strategy to meet the goals of
developing a functional assay for TB vaccine testing, and describe some of the chal-
lenges encountered in performing and transferring such assays.
KEYWORDS mycobacterial growth inhibition assay, MGIA, tuberculosis, correlates of
immunity, vaccines
The tuberculosis (TB) vaccine ﬁeld is severely hampered by the lack of deﬁnedimmune parameters that correlate with vaccine efﬁcacy in human studies. There
has been recent progress, such as the ﬁnding that antigen-speciﬁc gamma interferon
(IFN-) enzyme-linked immunosorbent spot assay (ELISpot) responses correlate with
reduced risk of developing disease in Mycobacterium bovis BCG-vaccinated South
African infants (1). However, heterogeneous BCG vaccine responses are observed and
may be associated with the immune environment at the time of vaccination, including
the proportions of monocytes and activated HLA-DR CD4 T cells (1, 2). Development
of a validated functional biological response assay capable of assessing the potential of
a vaccine-induced immune response to protect against Mycobacterium tuberculosis
infection or TB disease would represent a major advance in the effort to develop TB
vaccines. Such an assay would circumvent the need to identify or fully understand the
speciﬁc aspects of the immune response contributing to this effect. Mycobacterial
growth inhibition assays (MGIAs) represent one such clinically relevant approach. Using
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whole blood or peripheral blood mononuclear cells (PBMCs), MGIAs offer an unbiased
measure of the vaccine-induced antigen-speciﬁc immune response, taking into account
the ability of this response to function in its respective immune environment. MGIAs
also have the potential to decrease the time and resources required to evaluate a new
TB vaccine in preclinical studies.
The MGIA project brought together an international group of scientiﬁc experts to
work on growth inhibition assays from 2010 to 2014. Participants included researchers
from regions in which TB is endemic, such as Cape Town, South Africa, and areas in
which TB is not endemic, such as the United Kingdom and Washington, DC, St. Louis,
MO, New York, and Colorado in the United States.
GOALS OF THE MGIA PROJECT AND ASSAY SELECTION
The MGIA project was initially supported by a World Health Organization (WHO)
working group and was viewed as the follow-up project to a whole-blood enzyme-
linked immunosorbent assay (ELISA) that the WHO had recommended previously (3).
The aim was to develop a functional assay that could be applied in all clinical trials of
TB vaccine candidates, thus aiding the identiﬁcation of correlates of immunity. Al-
though several MGIAs had been described previously in the literature (recently re-
viewed in reference 4), little work had been done on qualifying an assay that could be
transferred across laboratories, using a standardized reproducible method for vaccine
assessment. This was a major goal of the project, which was funded by Aeras and the
U.S. Food and Drug Administration (FDA). Prior to 2010, most MGIA development had
focused on whole-blood systems and had shown promise (5–10). However, especially
given the logistical challenges associated with real-time processing of fresh blood
samples in clinical vaccine trials, efforts were made in this project to assess the potential
of using cryopreserved PBMCs and to compare the outcomes with those from whole
blood. The speciﬁc early goals were as follows: (i) to assess the variability, reproduc-
ibility, and transferability of four different MGIAs in naive, BCG-vaccinated, and BCG-
revaccinated subjects; (ii) to compare PBMC and whole-blood MGIA responses induced
by wild-type BCG and a new recombinant BCG vaccine; (iii) to determine the effect of
M. tuberculosis infection status on inhibition of mycobacterial growth in a population
where TB is endemic (South Africa); (iv) to test sera obtained from subjects enrolled in
the enhanced BCG vaccine MGIA study for antibodies to capsular and cell surface
constituents, including major polysaccharide antigens, and to compare the preimmu-
nization and postimmunization antibody levels with MGIA outcomes; and (v) to explore
other immune mechanisms underlying mycobacterial growth inhibition (e.g., by cor-
relation with ELISpot and intracellular cytokine staining ﬂow analyses of blood samples
from the BCG study cohorts).
Although four previously reported MGIAs were considered for initial evaluation, a
whole-blood assay based on the methods of Wallis et al. was selected as a focus for this
project, using the Bactec mycobacteria growth indicator tube (MGIT) system to quan-
titate mycobacterial growth (5) (referred to here as the direct MGIA). The rationale for
this decision included the relative simplicity of the assay and its use of standardized
reagents and equipment that are readily available in many clinical TB laboratories.
Furthermore, the assay had been used previously to demonstrate antimycobacterial
activity of bactericidal drugs that correlated with sterilizing activity observed during in
vivo therapy (5, 11). The Bactec MGIT system has several advantages over traditional
CFU-based methods of mycobacterial quantiﬁcation, as it utilizes oxygen depletion as
a detection method that is sensitive not only to the number of viable bacteria but also
to their rates of metabolism and growth. It is unaffected by clumping and does not
require serial dilutions, providing an accurate computer-generated readout based on
validated technology.
It was also agreed that an adaptation of this assay using cryopreserved PBMCs
should be developed and evaluated for comparison with whole-blood results. It is
widely accepted that the cellular immune response is central to protection against M.
tuberculosis and, although innate whole-blood components such as neutrophils are
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known to play a role in the host response, they may be less relevant for vaccine-
induced effects on adaptive immunity. Furthermore, the use of cryopreserved cells
could aid in transferability of the assay to different trial sites, eliminating the need to
evaluate samples in real time using fresh material. Rather, cells could be stored and
analyzed in the future, which not only is logistically simpler but also would negate the
need for a Bactec MGIT system at every site. Finally, the ability to use cryopreserved
cells would enable additional retrospective studies of samples from historical clinical
vaccine trials, for validation and exploratory work. A schematic diagram and a descrip-
tion of the method for the direct MGIA are provided in Fig. 1.
The studies involved in this project are presented chronologically; work began using
samples from clinical studies (as the ultimate goal was development of a human assay),
but the challenges encountered resulted in a decision to focus on preclinical adapta-
tions in the latter stages. One of the greatest impediments to initial MGIA develop-
mental efforts using human samples was the lack of availability of sufﬁciently large
single whole-blood or PBMC samples from recently BCG-vaccinated volunteers; this was
required for assay optimization and assessment of reproducibility between laboratories.
Using animal samples such as mouse splenocytes, however, it is possible to overcome
this issue, as 50 million to 100 million splenocytes may be isolated from each mouse.
Furthermore, the ability to select age- and sex-matched naive inbred animals removes
a number of potential sources of variability found in human clinical trials. Animal
models also provide the opportunity for biological validation by correlating assay
outcomes with protection from in vivo challenges with pathogenic M. tuberculosis (see
below).
Participants in the BCG vaccination and revaccination study were recruited under a
protocol approved by the Oxfordshire Research Ethics Committee. Written informed
consent was obtained from all individuals prior to enrollment in the trial. Human
studies performed at the South African Tuberculosis Vaccine Initiative (SATVI) were
approved by the Human Research Ethics Committee of the University of Cape Town. All
adult participants provided written informed consent prior to participation in the
studies. In the case of children, written informed consent was provided by a parent or
legal guardian. All of the work at Saint Louis University was approved by the Saint Louis
University Institutional Review Board, and PBMCs from independent healthy BCG-
vaccinated subjects were collected under a protocol approved by the Institutional
Review Board of the Albert Einstein College of Medicine. All animal studies were
approved by the appropriate institutions, which used IACUC-approved protocols and
FIG 1 Schematic of the MGIT mycobacterial growth inhibition assay method. Whole blood or cell culture medium
containing the appropriate concentration of PBMCs (or mouse splenocytes in mouse studies) is inoculated with an
equal volume of mycobacteria at a low MOI (1 CFU/10,000 PBMCs). Cultures are incubated in 2-ml tubes at 37°C
for 96 h, with 360° rotation. Cells are then lysed to remove red blood cells and/or to release intracellular
mycobacteria. The lysate is inoculated into Bactec MGITs. The tubes are placed in the Bactec 960 system and
incubated at 37°C until positivity is detected by ﬂuorescence. On day 0, direct-to-MGIT viability controls are set up
by directly inoculating MGIT tubes with the same volume of mycobacteria as the samples. The TTP data are
converted to log10 CFU values using a standard curve, and the ﬁnal values are expressed as absolute CFU values
or values relative to the control value, indicating the amount of growth inhibition that occurred during the culture
period.
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methods. At Public Health England, all animal procedures and the study design were
approved by the Public Health England, Porton Down, Ethical Review Committee and
were authorized under an appropriate U.K. Home Ofﬁce project license.
EARLY OPTIMIZATION WORK
BCG was selected as a surrogate for M. tuberculosis in the majority of these studies
to avoid the need for biosafety level 3 (BSL3) facilities. It was established previously that
measures of growth inhibition of BCG correlated with those of M. tuberculosis H37Rv in
a murine MGIA (12), and this was conﬁrmed in the direct MGIA (Fig. 2A). Early
experiments using the direct PBMC MGIA indicated high intra-assay variability between
replicate cultures. This was addressed by considering various aspects of assay prepa-
ration, the culture period, and 96-hour processing. It was determined that the standard
antibiotic supplement (penicillin and streptomycin) in the culture medium should not
be used at any stage of sample processing after thawing, due to the effect of artiﬁcially
reducing the inoculum (13). However, this altered the multiplicity of infection (MOI),
such that the vaccine effect was overwhelmed. A smaller inoculum resulted in in-
creased intra-assay variability. To maintain the same initial inoculum volume, a lower
MOI was achieved by using greater cell concentrations; although this did improve
reproducibility, a balance had to be reached, given the limiting factor of cell numbers
in many clinical trials. Experiments altering the MOI in the direct splenocyte MGIA have
been described (14). Once the optimal MOI was identiﬁed, variability in the inoculum
itself was addressed by comparing different declumping methods, such as vortex-
mixing, ﬁltering, and sonicating. Vortex-mixing with glass beads resulted in low intra-
assay variability while retaining high recovery of CFU. Other variables examined in-
cluded BCG strain (14), culture rotation methods, and lysis agents. Variability between
sites in whole-blood MGIA performance has yet to be deﬁned but could result from
factors such as differences in blood anticoagulants and inoculum strains.
HUMAN MGIA STUDIES
BCG vaccination and revaccination. A clinical trial of BCG vaccination and revac-
cination in U.K. adults was conducted at the University of Oxford (13). The direct PBMC
MGIA detected a signiﬁcant improvement in mycobacterial growth inhibition following
primary BCG vaccination, consistent with epidemiological data on the efﬁcacy of BCG
in this population. No improvement in mycobacterial growth inhibition was observed
following BCG revaccination, using either the whole-blood or PBMC assay (13). This is
in contrast to a previous study with U.S. volunteers, in which the direct whole-blood
MGIA, as well as the primary lymphocyte MGIA (effector lymphocytes added to infected
FIG 2 Direct whole-blood MGIA for South African infants. (A) Whole-blood samples from 10 South African
infants were assessed using the direct whole-blood MGIA. There was a signiﬁcant correlation between
growth of BCG SSI and M. tuberculosis (M.tb) H37Rv (Spearman’s r  0.73; P  0.02). (B) Whole-blood
samples from 10 South African infants were compared with those from 53 South African adults using the
direct whole-blood MGIA. There was a signiﬁcant reduction in growth of BCG SSI in infants, compared
with adults. *, P  0.05, Mann-Whitney U test between groups.
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autologous monocytes [9]) and the secondary lymphocyte MGIA (using antigen-
expanded T cells [6]), detected enhanced mycobacterial growth inhibition after BCG
revaccination (7).
In the Oxford study, the direct PBMC MGIA demonstrated a stronger primary vaccine
effect and greater reproducibility over repeated baseline bleeds, compared with whole
blood (13), most likely due to the processing of longitudinal PBMC samples in one
batch. This is not an option for fresh blood, which may suffer from batch effects,
including those associated with different vials of mycobacterial inoculum. However, this
was not the case in other studies, such as the AERAS-422 vaccine trial at Saint Louis
University described below, in which the direct whole-blood MGIA proved less variable
among subjects included in each vaccinated group, compared to primary, secondary, or
titrated PBMC MGIAs (15).
An additional study was conducted in South Africa, comparing 10-week-old infants
who were BCG vaccinated at birth with older adults. Infants demonstrated enhanced
ability to inhibit growth of BCG SSI (but not M. tuberculosis H37Rv) in the direct
whole-blood MGIA, compared with adults (Fig. 2B). These data suggest that BCG
vaccination may induce preferential growth inhibition of BCG even in newborns.
Study of immune correlates of risk. Recently, Fletcher et al. reported the ﬁndings
of a study on the immune correlates of risk among BCG-vaccinated infants in South
Africa (1). In that population, BCG-speciﬁc IFN- ELISpot responses and levels of
Ag85A-speciﬁc IgG antibodies measured at 4 to 6 months of age were associated with
reduced risk of developing TB disease over the next 3 years of life (1). However, the
ability to control mycobacterial growth in the direct PBMC MGIA was not associated
with reduced risk of TB disease. This could be due to the very low frequency of
BCG-speciﬁc IFN--secreting T cells (median of50 spot-forming cells/1 million PBMCs)
and the fact that small numbers of PBMCs were used in the assay (it has since been
established that the direct MGIA is more robust when greater numbers of PBMCs are
used). Furthermore, autologous serum was not used in the assay; therefore, the assay
would not have measured the contribution of Ag85A-speciﬁc IgG, or any other anti-
body, to growth inhibition (1). The study was also performed prior to subsequent
further optimization of the assay.
Comparison of wild-type BCG and a new recombinant BCG vaccine. Hoft et al.
performed the direct whole-blood MGIA as part of a clinical trial of AERAS-422, a live
recombinant BCG expressing perfringolysin and three M. tuberculosis antigens, namely,
85A, 85B, and Rv3407 (15). Between November 2010 and August 2011, 24 volunteers
were enrolled (AERAS-422, high dose, n 8; AERAS-422, low dose, n 8; Tice BCG, n
8). High-dose AERAS-422 vaccination induced Ag85A- and Ag85B-speciﬁc lymphopro-
liferative responses and marked antimycobacterial activity detectable in the direct
whole-blood MGIA (15). A systems biology approach using modular analysis identiﬁed
positive correlations between postvaccination T cell gene expression and MGIA activity
and negative correlations between postvaccination monocyte gene expression mod-
ules and MGIA activity. Unfortunately, the development of varicella-zoster virus reac-
tivations occurred in two of eight vaccine recipients given the high dose of AERAS-422,
resulting in discontinuation of AERAS-422 clinical development. However, these results
demonstrated that the direct whole-blood MGIA could detect vaccine-induced in-
creases in antimycobacterial immune activity (15).
Assessment of M. tuberculosis infection status. As described, there was a signif-
icant correlation in outcomes using BCG and M. tuberculosis in the direct whole-blood
MGIA. However, no difference in the magnitude of growth inhibition was detected
between healthy M. tuberculosis-infected and noninfected subjects, using either myco-
bacterial strain, in a region of South Africa in which TB is endemic (R. Baguma and T. J.
Scriba, unpublished observations). This was in contrast to a previous study in which
levels of growth of luminescent mycobacteria were signiﬁcantly lower in blood from
tuberculin skin test (TST)-positive subjects, compared with TST-negative subjects, in a
region in which TB is not endemic (10). The discordance between these ﬁndings might
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have resulted from the cross-sectional designs, in which infection with M. tuberculosis
was deﬁned using a single IFN- release assay or TST, and it is not known whether
volunteers from either study were recently or historically exposed to M. tuberculosis.
Furthermore, despite being QuantiFERON negative, the South African volunteers had
readily detectable T cell responses to BCG stimulation, suggesting high levels of
immunological sensitization to mycobacteria (likely due to childhood BCG vaccination
and/or exposure to environmental mycobacteria).
IMMUNE MECHANISMS OF GROWTH INHIBITION
One major goal of this project was to elucidate immune mechanisms underlying the
mycobacterial growth inhibition observed. The inﬂuences of IFN--producing T cells,
antibodies, monocyte/lymphocyte (ML) ratios, and hemoglobin (Hb) were assessed.
IFN--producing T cells. The magnitude of mycobacterial growth inhibition fol-
lowing BCG vaccination in the Oxford study did not correlate with the antigen-speciﬁc
IFN- ELISpot response, and a boosted IFN- ELISpot response observed following BCG
revaccination was not reﬂected in enhanced MGIA activity (13). Among the South
African volunteers, although QuantiFERON-TB Gold-positive individuals had greater
levels of ESAT-6- and CFP-10-speciﬁc IFN--secreting T cells, this did not translate into
improved MGIA responses. These ﬁndings are consistent with previous observations
that in vitro mycobacterial growth inhibition does not correlate with IFN- production
(7, 8).
Antibodies. Chen et al. demonstrated that IgG antibody responses to arabinoman-
nan (AM), a mycobacterial envelope polysaccharide, increased signiﬁcantly following
BCG vaccination, using samples from the Oxford trial (16). Their studies suggested that
such antibodies, particularly when targeting speciﬁc oligosaccharide epitopes, may play
a functional role in mycobacterial growth inhibition. Phagocytosis and intracellular
growth inhibition were signiﬁcantly enhanced when BCG was opsonized with postvac-
cination sera, and the enhancements correlated with IgG titers to AM. Furthermore,
increased phagolysosomal fusion in M. tuberculosis-infected macrophages was ob-
served with postvaccination serum but not prevaccination serum, indicating that
intracellular growth reduction was FcR mediated. Interestingly, the authors also found
that the antibody response at 4 weeks after BCG vaccination correlated with mycobac-
terial growth inhibition in the direct PBMC MGIA (16). A functional role of antibodies to
AM has since been further supported by murine immunization studies with AM
conjugate vaccines (17). These data highlight the importance of assessing the humoral
compartment in MGIAs and comparing PBMC- and whole-blood-based approaches to
better assess the potential contributions of antibody-mediated responses.
Monocyte/lymphocyte ratio. In blood samples from healthy volunteers, a greater
proportion of monocytes with respect to lymphocytes (higher ML ratio) is associated
with increased mycobacterial growth and increased probability of a type I IFN tran-
scriptional signature (18). Altering the ML ratio in vitro affects the control of mycobac-
terial growth, with either very high or very low ML ratios being associated with poorer
control in the direct PBMC MGIA (18). This is consistent with the observations that
profoundly altered ML ratios were associated with increased risk of developing TB
disease among non-HIV-exposed infants, HIV-exposed uninfected infants, HIV-positive
adults starting antiretroviral therapy, and postpartum women (2, 19–21). Accordingly,
Hoft et al. showed that antimycobacterial immune activity correlated positively with T
cell expression signatures and negatively with monocyte expression signatures in the
AERAS-422 study (15). Further studies with animal models may better deﬁne the
subpopulations of monocytes and lymphocytes important for mycobacterial growth
inhibition.
Hemoglobin. Using samples from the Oxford BCG vaccination study, a positive
correlation was observed between mean corpuscular Hb levels and mycobacterial
growth in the direct whole-blood MGIA (22). Experimental addition of Hb or ferric iron
to PBMCs from both humans and nonhuman primates (NHPs) resulted in increased
mycobacterial growth, an effect reversed by addition of the iron chelator deferoxamine.
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Furthermore, expression of Hb-related genes correlated signiﬁcantly with mycobacte-
rial growth in whole blood and, to a lesser extent, in PBMCs (22). This association
between Hb/iron levels and mycobacterial growth may in part explain differences in
outcomes between whole-blood and PBMC MGIAs and should be taken into account
when using these assays.
ANIMAL MGIA STUDIES
Given that early clinical studies indicate the need for more investigations before a
human PBMC MGIA can be qualiﬁed, MGIA development using animal models of TB
represents an important ongoing strategy. In addition to the beneﬁts regarding sample
volume and reduced heterogeneity described above, animal models have the impor-
tant advantage that the MGIA outcomes could be correlated with protection from in
vivo challenges with pathogenic M. tuberculosis, which would then biologically validate
the assay as being capable of assessing effective antimycobacterial immunity. Where
there is a need to test vaccine candidates for antigen dose, adjuvant dose, or antigen-
adjuvant combinations, MGIAs could save time, animals, and funds. As the direct MGIA
does not depend on any species-speciﬁc immune reagents, it can be easily adapted for
use across a range of animal species.
In an effort to improve intersite reproducibility, the animal phase of the MGIA
project utilized a single shared batch of frozen mycobacteria. The BCG batch was
prepared at Aeras and tested for viability and reproducibility prior to distribution to
project partners. Investigators also agreed that, for each experiment, the CFU of
mycobacterial stocks would be determined and standard curves would be used to
convert Bactec MGIT time-to-positivity (TTP) data to log10 CFU for the growth counts,
for ease of data presentation and interpretation.
Mouse model. A MGIA using infected macrophages cultured separately frommouse
splenocytes, and then combined, previously demonstrated reproducible growth inhi-
bition data at 7 days of incubation (23). Using this MGIA, immune splenocytes from
mice vaccinated with ﬁve different TB vaccines limited mycobacterial growth in vitro,
compared to naive controls. Importantly, the vaccine-induced MGIA correlated at a
group level with protective immune responses induced in experimentally matched
animals, using a mouse model of pulmonary TB (23).
More recent studies have focused on simplifying the mouse MGIA model. Marsay et
al. showed that the direct MGIA using splenocytes has the ability to detect mycobac-
terial growth inhibition following BCG vaccination (24). Furthermore, investigators from
the Center for Biologics Evaluation and Research (CBER), FDA, used the direct spleno-
cyte MGIA to demonstrate reproducible in vitro protective responses from mice immu-
nized with either BCG or a subunit vaccine, and they showed that the responses
correlated on a group level with in vivo protection data from experimentally matched
mice (25). They also conﬁrmed that mycobacterial quantiﬁcation using the Bactec MGIT
system correlated strongly with plating of organ homogenates and CFU counting and
is faster and easier to perform than the traditional CFU method (26).
BCG gives a robust and reproducible protective effect against challenge with M.
tuberculosis in C57BL/6 mice; therefore, this model has been used for further optimi-
zation of the mouse direct MGIA. Zelmer et al. sought to enhance the sensitivity of the
direct splenocyte MGIA and found that detection of vaccine-induced inhibition could
be improved by decreasing the MOI (27). It was also shown that the capacity to detect
mycobacterial growth inhibition in BCG-vaccinated mice was time sensitive, with
growth inhibition being detected only at the peak of the BCG immune response
(approximately 6 weeks in C57BL/6 mice) (14). As there is no ampliﬁcation of the
antigen-speciﬁc immune response in the direct MGIA, it is only the ability of the cells
resident in the spleen at the time of harvest that can be assessed for antimycobacterial
capacity (14). Since BCG is a live replicating mycobacterium, there can be variations in
the development of the peak of the immune response and variations in the persistence
of BCG vaccine in lungs and spleen; this can affect the ability to reproducibly select the
optimal time point for measuring vaccine responses (28, 29). However, selecting the
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time point for the peak immune response may be a lesser challenge in assessing a
subunit vaccine, and the ability of MGIAs to assess the effectiveness of subunit vaccines
has shown early promise (23).
Guinea pig model. Investigators at Colorado State University and Public Health
England are in the process of adapting the direct MGIA for use with a guinea pig model.
Early indications are that PBMCs provide more robust information than does whole
blood, and further studies with vaccine candidates to examine the utility of PBMC
MGIAs in the guinea pig model are in progress.
NHP model. The direct whole-blood MGIA has been adapted for use with NHP
samples at the University of Oxford, in collaboration with Sharpe and colleagues at
Public Health England. In a study of seven rhesus macaques, the assay demonstrated
strong enhancement of mycobacterial growth inhibition following BCG vaccination,
which was still signiﬁcant following correction for changes in hemoglobin levels (22).
Work is currently ongoing to optimize the NHP direct PBMC MGIA and to correlate the
outcomes with protection from in vivo BCG and M. tuberculosis challenges, on an
individual animal basis. Reproduction of the MGIA in NHPs could help to inform human
studies and to provide biological validation of the assay.
CONCLUSIONS
The MGIA represents a functional assay for assessing TB vaccine activity, which has
the potential to correlate with vaccine-induced immune protection. To date, the direct
whole-blood MGIA has demonstrated the most consistent effects across a range of
different clinical vaccine studies in humans. However, because this assay must be
performed within hours after blood drawing, it requires laboratory infrastructure close
to the clinical site, making it difﬁcult to assess in many vaccine trials, particularly in
countries in which TB is endemic. Cryopreserved PBMCs are thus the preferred speci-
men type for logistical reasons, and the direct PBMC MGIA is currently undergoing
further optimization and harmonization across laboratories as part of the European
Research Infrastructures for Poverty Related Diseases collaborative infrastructure pro-
gram (H. McShane and R. Tanner, personal communication). Use of MGIAs in animal
models of TB provides an opportunity for biological validation with respect to protec-
tion from pathogenic in vivo challenges and could be more time- and cost-effective.
Animal MGIAs could also reduce the number of virulent M. tuberculosis challenge
experiments required to identify promising vaccine candidates for progression to
clinical trials (30).
The results presented indicate that the MGIA has promise as a functional assay for
the assessment of candidate TB vaccines. It also provides a tractable model for
investigating the mechanisms involved in antimycobacterial immunity. For example,
ﬁndings from this project have highlighted the importance of both lymphoid and
myeloid cell-mediated immunity and antibody-mediated immunity in these assays. It
would be interesting to consider how exposure of an individual to other mycobacterial
species or infections (such as helminths) would affect the ability to control mycobac-
terial growth in vitro, and work to this end is under way. The inﬂuence of regulatory
immune mechanisms and suppressors, which would be represented in unbiased sam-
ples such as whole blood and PBMCs, should also be explored.
In this report, we have summarized the numerous accomplishments of this project.
Many parameters of a standardized MGIA that can be routinely performed in labora-
tories with access to Bactec MGIT equipment have been established. However, MGIAs
are technically demanding, and it is clear that further work is required, particularly to
reduce the variability intrinsic to functional assays. Use of cryopreserved PBMCs remains
a challenge, as does the goal of qualifying this assay for use in human studies in
particular. Utilization of the direct MGIA in animal models (especially mice and NHPs)
for assessment of new TB vaccines seems more valuable at this time. A number of
explorations of MGIAs as functional TB tests should be performed in the future, and
some of these goals are as follows: (i) to demonstrate that the direct PBMC MGIA meets
requirements as a qualiﬁed assay; (ii) to determine whether there are signiﬁcant
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differences when BCG or M. tuberculosis strains are used for in vitro infection; (iii) to
evaluate differences when MGIAs are used in countries in which TB is endemic or not
endemic; (iv) to determine whether MGIAs can be used in M. tuberculosis-infected
populations; (v) to identify factors in PBMCs and whole blood that mediate and
inﬂuence growth inhibition; (vi) to evaluate the performance of the PBMC MGIT assay
in trials of novel TB vaccine candidates; (vii) to determine whether the test is repro-
ducible at different sites; and (viii) to determine whether the direct whole-blood MGIA
can be further adapted or reﬁned for use in vaccine or TB studies. If MGIAs were
validated and shown to correlate reproducibly and consistently with efﬁcacy demon-
strated in clinical trials of candidate vaccines for TB, they would hold great potential.
Much as neutralizing antibodies are currently used to assess the efﬁcacy of certain other
vaccines, MGIA results could be applied for regulatory purposes, as a surrogate marker
of efﬁcacy.
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